• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

释放低剂量左炔诺孕酮阴道环的药代动力学和药效学研究。

Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel.

作者信息

Xiao B L, Zhang X L, Feng D D

出版信息

Contraception. 1985 Nov;32(5):455-71. doi: 10.1016/0010-7824(85)90016-2.

DOI:10.1016/0010-7824(85)90016-2
PMID:3936678
Abstract

Pharmacokinetic and pharmacodynamic effects of a vaginal ring releasing 20 micrograms/day levonorgestrel (L-NOG) have been studied in 15 women. Serum levels of L-NOG, estradiol and progesterone were measured three times a week in a control menstrual cycle and a treatment period of 3 months after the insertion of the first vaginal ring. All control cycles were normal ovulatory. Among the 36 treatment cycles 13 were ovulatory (36%), 5 ovulatory with inadequate luteal function (14%), 14 anovulatory but with marked follicle activity (39%) and 4 anovulatory (11%). In the groups with ovulatory reaction the serum levels of L-NOG showed a decline of 54% of the initial level at the end of the treatment period, calculated according to the linear regression equation of Y = 0.903-0.0142X, while in the groups without ovulation the L-NOG levels were higher and the decline was 24% of the initial level (Y = 1.034-0.0086X). There were distinct individual differences in the levels of L-NOG and ovarian reactions. Marked follicle activity with very high estradiol levels were found in correlation with high L-NOG in 7 treatment cycles, particularly in the B type of reaction (B = anovulatory cycle with marked follicle activity). More intermenstrual bleeding and spotting occurred in the second treatment cycles, particularly in those with anovulatory reactions.

摘要

对15名女性研究了每日释放20微克左炔诺孕酮(L-NOG)的阴道环的药代动力学和药效学效应。在对照月经周期以及插入第一个阴道环后的3个月治疗期内,每周3次测量血清中的L-NOG、雌二醇和孕酮水平。所有对照周期排卵均正常。在36个治疗周期中,13个为排卵周期(36%),5个排卵周期但黄体功能不足(14%),14个无排卵但卵泡活动明显(39%),4个无排卵(11%)。在有排卵反应的组中,根据Y = 0.903 - 0.0142X的线性回归方程计算,治疗期末血清L-NOG水平下降至初始水平的54%,而在无排卵的组中,L-NOG水平较高,下降至初始水平的24%(Y = 1.034 - 0.0086X)。L-NOG水平和卵巢反应存在明显的个体差异。在7个治疗周期中,发现明显的卵泡活动且雌二醇水平非常高与高L-NOG相关,特别是在B型反应中(B = 无排卵周期但卵泡活动明显)。在第二个治疗周期中出现更多的经间期出血和点滴出血,特别是在无排卵反应的周期中。

相似文献

1
Pharmacokinetic and pharmacodynamic studies of vaginal rings releasing low-dose levonorgestrel.释放低剂量左炔诺孕酮阴道环的药代动力学和药效学研究。
Contraception. 1985 Nov;32(5):455-71. doi: 10.1016/0010-7824(85)90016-2.
2
Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.对以恒定、接近零级速率释放左炔诺孕酮的阴道给药装置进行的药代动力学和药效学研究。
Contraception. 1982 Dec;26(6):567-85. doi: 10.1016/0010-7824(82)90132-9.
3
Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.左炔诺孕酮宫内节育器的药代动力学和药效学研究。
Contraception. 1990 Apr;41(4):353-62. doi: 10.1016/0010-7824(90)90035-t.
4
The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Contraception. 1985 Apr;31(4):431-9. doi: 10.1016/0010-7824(85)90009-5.
5
A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.左炔诺孕酮新型阴道给药系统的临床药理学研究
Contraception. 1985 Dec;32(6):581-601. doi: 10.1016/s0010-7824(85)80004-4.
6
Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 micrograms/24 h when used alone or in combination with transdermal systems releasing estradiol.
Contraception. 1994 Jul;50(1):87-100. doi: 10.1016/0010-7824(94)90083-3.
7
Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 micrograms/24 hours: a pilot study.
Contraception. 1994 Feb;49(2):139-50. doi: 10.1016/0010-7824(94)90089-2.
8
The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.在月经周期不同阶段大剂量给予左炔诺孕酮对卵巢功能和子宫内膜形态的影响。
Contraception. 1989 Mar;39(3):275-89. doi: 10.1016/0010-7824(89)90060-7.
9
Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.使用左炔诺孕酮宫内节育器期间的血浆左炔诺孕酮水平和卵巢功能
Contraception. 1989 Feb;39(2):195-204. doi: 10.1016/s0010-7824(89)80008-3.
10
Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.释放炔诺酮和雌二醇的避孕阴道环的药效学:卵巢功能、出血控制及脂蛋白模式
Ups J Med Sci. 1984;89(2):179-88. doi: 10.3109/03009738409178478.

引用本文的文献

1
Next-generation 3D printed multipurpose prevention intravaginal ring for prevention of HIV, HSV-2, and unintended pregnancy.下一代 3D 打印多功能预防阴道环,用于预防 HIV、HSV-2 和非意愿性怀孕。
J Control Release. 2024 Dec;376:1209-1224. doi: 10.1016/j.jconrel.2024.10.059. Epub 2024 Nov 12.
2
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.在肯尼亚女性中进行的替诺福韦以及替诺福韦加左炔诺孕酮缓释阴道环的安全性、药代动力学和药效学的随机对照IIa期临床试验。
Front Reprod Health. 2023 Jun 13;5:1118030. doi: 10.3389/frph.2023.1118030. eCollection 2023.
3
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
一项随机、安慰剂对照的 I 期临床试验,评估了连续或周期性使用 90 天替诺福韦加左炔诺孕酮阴道环的安全性、药代动力学、药效学和可接受性:CONRAD 138 研究。
PLoS One. 2022 Oct 10;17(10):e0275794. doi: 10.1371/journal.pone.0275794. eCollection 2022.
4
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.随机、安慰剂对照的 I 期临床试验,评估了替诺福韦和替诺福韦加左炔诺孕酮阴道环在女性中的安全性、药代动力学、药效学和可接受性。
PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018.
5
An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.一种阴道环,能释放三种抗病毒药物和一种避孕药,可阻断 SHIV-RT 感染,减少 HSV-2 脱落,并抑制恒河猴的激素循环。
Drug Deliv Transl Res. 2017 Dec;7(6):840-858. doi: 10.1007/s13346-017-0389-0.
6
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.作为杀微生物剂和多用途预防技术递送系统的阴道环。
Int J Womens Health. 2013 Oct 21;5:695-708. doi: 10.2147/IJWH.S34030.
7
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.多用途预防技术:预防HIV-1、HSV-2和意外怀孕的生物医学工具。
Infect Dis Obstet Gynecol. 2011;2011:1-10. doi: 10.1155/2011/429403. Epub 2011 Aug 9.
8
Clinical pharmacokinetics of contraceptive steroids. An update.甾体避孕药的临床药代动力学。最新进展。
Clin Pharmacokinet. 1991 Jan;20(1):15-37. doi: 10.2165/00003088-199120010-00002.